Singular Genomics Appoints Elaine R. Mardis, Ph.D., Pioneer in Genomics Research, to Board of Directors
La Jolla, California, January 6, 2022 – Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company that harnesses new next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced the addition of Elaine R Tuesdays, Ph.D., to the Company’s Board of Directors. Dr. Mardis is an internationally recognized pioneering researcher in cancer genomics and focuses on the application of genomic technologies to improve understanding of human diseases and the accuracy of medical diagnosis, prognosis and treatment.
“We are delighted that Elaine is joining the Board of Directors. She brings the rare combination of world-class scientific, industrial and governance talent to this role. As a distinguished researcher and leader in cancer genomics – whose work in DNA sequencing has led to significant advances in understanding genetic mutations and their link to cancer – Elaine will provide invaluable information to our team. Said Drew Spaventa, President and CEO of Singular Genomics. “Singular Genomics is first and foremost a science and technology company. In addition to a solid scientific and technical background, Elaine’s unique position as a leader in precision medicine leading clinical applications of genomics lends itself to our long-term goal of providing superior clinical sequencing solutions. ”
Since 2016, Dr Mardis has been Co-Executive Director of the Institute of Genomic Medicine at Nationwide Children’s Hospital and holds the Steve and Cindy Rasmussen Chair in Genomic Medicine. She is also a professor of pediatrics at the Ohio State University College of Medicine. In addition, Dr. Mardis sits on the Supervisory Board, the Science and Technology Committee, and the Compensation and Human Resources Committee of Qiagen. She is currently Associate Editor-in-Chief of the peer-reviewed journal Models and mechanisms of the disease, co-editor-in-chief of Cancer Research Communications, and editor-in-chief of Molecular case studies. Previously, Dr. Mardis was a faculty member at the Washington University School of Medicine for 22 years. Dr. Mardis obtained her Bachelor of Science in Zoology and her Doctorate. in Chemistry and Biochemistry, both from the University of Oklahoma. She has authored over 380 peer-reviewed journal articles, has authored chapters for several medical textbooks, and is an elected member of the United States National Academy of Medicine.
“Following the recent launch of the G4 sequencing platform, Singular is well positioned to become a leader in the next generation sequencing space, with impressive technology and a strong team committed to improving human health,” said Dr Mardis. “I look forward to working with Drew, the leadership team and the board of directors to support the continued evolution of Singular’s sequencing technologies that will help advance science and medicine. ”
About Singular Genomics Systems, Inc.
Singular Genomics is a life science technology company that harnesses new next-generation sequencing (NGS) and multiomics technologies to create products that empower researchers and clinicians. Our mission is to accelerate genomics for the advancement of science and medicine. Our singular sequencing engine is the fundamental platform technology that forms the basis of our developing products as well as the core principles of our products: precision, speed, flexibility and power. We are currently developing two integrated solutions specifically designed to target the applications where these product fundamentals matter most. Our first integrated solution, the G4 sequencing platform, is aimed at the NGS market. Our second integrated solution in development, the PX, combines unique cell analysis, spatial analysis, genomics and proteomics in one integrated instrument to provide a versatile multiomics solution. The G4 and PX sequencing platforms both consist of an instrument and an associated menu of consumable kits.
Certain statements contained in this press release, other than historical information, may constitute forward-looking statements within the meaning of federal securities laws. Such forward-looking statements are based on our management’s current expectations and are subject to a number of risks and uncertainties that could cause our actual future results to differ materially from our management’s current expectations or those suggested by forward-looking statements. These risk factors that may affect our future operating results are identified and described in more detail in our filings with the SEC, including our Quarterly Report on Form 10-Q for the period ended September 30, 2021, filed with the SEC on Nov. 9. 2021. Therefore, you should not rely on forward-looking statements as predictions of future events or our future performance. Unless required by applicable law, we do not undertake to publicly update or revise any forward-looking statements contained in this document, whether as a result of new information, future events, or changes in circumstances. or otherwise.
Dan Budwick, 1AB
Singular Genomics Systems Inc. published this content on 06 January 2022 and is solely responsible for the information it contains. Distributed by Public, unedited and unmodified, on 06 January 2022 09:27:13 PM UTC.
Public now 2022
Technical Analysis Trends SINGULAR GENOMICS SYSTEMS, INC.
|Short term||Mid Road||Long term|
Evolution of the income statement
|Average consensus||TO BUY|
|Number of analysts||5|
|Last closing price|
|Average price target|
|Spread / Average target||192%|